{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:01:53Z","timestamp":1758272513036},"reference-count":28,"publisher":"Japan Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1507\/endocrj.ej17-0155","type":"journal-article","created":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T22:10:42Z","timestamp":1504908642000},"page":"1173-1180","source":"Crossref","is-referenced-by-count":9,"title":["Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension"],"prefix":"10.1507","volume":"64","author":[{"given":"Mari","family":"Satoh","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Toho University Omori Medical Center, Tokyo 143-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Aso","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Toho University Omori Medical Center, Tokyo 143-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Toho University Omori Medical Center, Tokyo 143-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Saji","sequence":"additional","affiliation":[{"name":"Advanced and Integrated Cardiovascular Research Course in the Young and Adolescence, Toho University, Tokyo 143-8540, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1.\tSimonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, <i>et al<\/i>. (2013) Updated clinical classification of pulmonary hypertension.  <i>J Am Coll Cardiol<\/i> 62:  D34-41.","DOI":"10.1016\/j.jacc.2013.10.029"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2.\tElliott CG (2013) Genetics of pulmonary arterial hypertension. <i>Clin Chest Med<\/i> 34: 651-663.","DOI":"10.1016\/j.ccm.2013.08.003"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3.\tChu JW, Kao PN, Faul JL, Doyle RL (2002) High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. <i>Chest<\/i> 122: 1668-1673.","DOI":"10.1378\/chest.122.5.1668"},{"key":"4","unstructured":"4.\tCastillo Palma MJ, Garc&iacute;a Her&aacute;ndez FJ, Montero Benavides P, Gonz&aacute;lez Le&oacute;n R, Oca&ntilde;a Medina C, <i>et al<\/i>. (2009) Thyroid dysfunction in patients with pulmonary arterial hypertension. A cohort study of 58 patients. <i>Med Clin (Barc)<\/i> 132: 695-700 (In Spanish)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5.\tChadha C, Pritzker M, Mariash CN (2009) Effect of epoprostenol on the thyroid gland: enlargement and secretion of thyroid hormone. <i>Endocr Pract<\/i> 15: 116-121.","DOI":"10.4158\/EP.15.2.116"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6.\tSatoh M, Aso K, Nakayama T, Naoi K, Ikehara S, <i>et al<\/i>. (2010) Autoimmune thyroid disease in children and adolescents with idiopathic pulmonary arterial hypertension. <i>Circ J<\/i> 74: 371-374.","DOI":"10.1253\/circj.CJ-09-0369"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7.\tTrapp CM, Elder RW, Gerken AT, Sopher AB, Lerner S, <i>et al<\/i>. (2012) Pediatric pulmonary arterial hypertension and hyperthyroidism: a potentially fatal combination. <i>J Clin Endocrinol Metab<\/i> 97: 2217-2222.","DOI":"10.1210\/jc.2012-1109"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8.\tRabinovitch M, Guignabert C, Humbert M, Nicolls MR (2014) Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. <i>Circ Res<\/i> 115: 165-175.","DOI":"10.1161\/CIRCRESAHA.113.301141"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9.\tKonno N, Yuri K, Taguchi H, Miura K, Taguchi S, <i>et al<\/i>. (1993) Screening for thyroid disease in an iodine sufficient area with sensitive thyrotropin assays, and serum thyroid autoantibody and urinary iodine determinants. <i>Clin Endocrinol (Oxf)<\/i> 38: 273-281.","DOI":"10.1111\/j.1365-2265.1993.tb01006.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10.\tTakasu N, Yamada T, Shimizu Y (1981) An important role of prostacyclin in porcine thyroid cells in culture. Stimulation and refractoriness of cyclic AMP synthesis and iodine metabolism. <i>FEBS Lett<\/i> 129: 83-88.","DOI":"10.1016\/0014-5793(81)80761-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11.\tKasai K, Hiraiwa M, Suzuki Y, Banba N, Emoto T, <i>et al<\/i>. (1986) Prostacyclin stimulation of adenylate cyclase activity in human thyroid membranes. <i>Horm Metab Res<\/i> 18: 625-629.","DOI":"10.1055\/s-2007-1012390"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12.\tGali&egrave; N, Corris PA, Frost A, Girgis RE, Granton J, <i>et al<\/i>. (2013) Updated treatment algorithm of pulmonary arterial hypertension. <i>J Am Coll Cardiol<\/i> 62: D60-72.","DOI":"10.1016\/j.jacc.2013.10.031"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13.\tBoswell MG, Zhou W, Newcomb DC, Peebles RS Jr (2011) PGI2 as a regulator of CD4+ subset differentiation and function. <i>Prostaglandins Other Lipid Mediat<\/i> 96: 21-26.","DOI":"10.1016\/j.prostaglandins.2011.08.003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14.\tLiu W, Li H, Zhang X, Wen D, Yu F, <i>et al<\/i>. (2013) Prostaglandin I2-IP signaling regulates human Th17 and Treg cell differentiation. <i>Prostaglandins Leukot Essent Fatty Acids<\/i> 89: 335-344.","DOI":"10.1016\/j.plefa.2013.08.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15.\tTanaka K, Yoshioka K, Tatsumi K, Kimura S, Kasuya Y (2014) Endothelin regulates function of IL-17-producing T cell subset. <i>Life Sci<\/i> 118: 244-247.","DOI":"10.1016\/j.lfs.2014.01.084"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16.\tGuo Y, Chung SK, Siu CW, Kwan SC, Ho PW, <i>et al<\/i>. (2014) Endothlin-1 overexpression exacerbates experimental allergic encephalomyelitis. <i>J Neuroimmunol<\/i> 276: 64-70.","DOI":"10.1016\/j.jneuroim.2014.08.616"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17.\tPifarr&eacute; P, Gutierrez-Mecinas M, Prado J, Usero L, Roura-Mir C,    <i>et al<\/i>. (2014) Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. <i>Exp Neurol<\/i> 251: 58-71.","DOI":"10.1016\/j.expneurol.2013.10.021"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18.\tNanba T, Watanabe M, Inoue N, Iwatani Y (2009) Increases of the Th1\/Th2 cell ratio in severe Hashimoto&rsquo;s disease and in the proportion of Th17 cells in intractable Graves&rsquo; disease. <i>Thyroid<\/i> 19: 495-501.","DOI":"10.1089\/thy.2008.0423"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19.\tPeng D, Xu B, Wang Y, Guo H, Jiang Y (2013) A high frequency of circulating Th22 and Th17 cells in patients with new onset Graves&rsquo; disease. <i>PLoS One<\/i> 8: e68446.","DOI":"10.1371\/journal.pone.0068446"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20.\tFigueora-Vega N, Alfonso-P&eacute;rez M, Benedicto I, S&aacute;nchez-Madrid F, Gonz&aacute;lez-Amaro R, <i>et al<\/i>. (2010) Increased circulating pro-inflammatory cytokine and Th17 lymphocytes in Hashimoto&rsquo;s thyroiditis. <i>J Clin Endocrinol Metab<\/i> 95: 953-962.","DOI":"10.1210\/jc.2009-1719"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21.\tHorie I, Abiru N, Saitoh O, Ichikawa T, Iwakura Y, <i>et al<\/i>. (2011) Distinct role of T helper type 17 immune response for Graves&rsquo; hyperthyroidism in mice with different genetic backgrounds. <i>Autoimmunity<\/i> 44: 159-165.","DOI":"10.3109\/08916931003777247"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22.\tHorie I, Abiru N, Nagayama Y, Kuriya G, Saitoh O, <i>et al<\/i>. (2009) T helper type 17 immune response plays an indispensable role for development of iodine-induced autoimmune thyroiditis in nonobese diabetic-H2h4 mice. <i>Endocrinology<\/i> 150: 5135-5142.","DOI":"10.1210\/en.2009-0434"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23.\tRoberts KE, Barst RJ, McElroy JJ, Widlitz A, Chada K, <i>et al<\/i>. (2005) Bone morphogenetic protein receptor 2 mutations in adults and children with idiopathic pulmonary arterial hypertension: association with thyroid disease. <i>Chest<\/i> 128: 618S.","DOI":"10.1378\/chest.128.6_suppl.618S"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24.\tHautefort A, Girerd B, Montani D, Cohen-Kaminsky S, Price L, <i>et al<\/i>. (2015) T-helper 17 cell polarization in pulmonary arterial hypertension. <i>Chest<\/i> 147: 1610-1620.","DOI":"10.1378\/chest.14-1678"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25.\tHashimoto-Kataoka T, Hosen N, Sonobe T, Arita Y, Yasui T, <i>et al<\/i>. (2015) Interleukin-6\/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension. <i>Proc Natl Acad Sci USA<\/i> 112: E2677-2686.","DOI":"10.1073\/pnas.1424774112"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26.\tGarc&iacute;a-Hern&aacute;ndez FJ, Oca&ntilde;a-Media C, Gonzalez-Leon R, Garrido-Rasco R, S&aacute;nchez-Rom&aacute;n J (2006) Autoimmune polyglandular syndrome and pulmonary arterial hypertension. <i>Eur Respir J<\/i> 27: 657-658.","DOI":"10.1183\/09031936.06.00133505"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27.\tAlghamdi MH, Steinraths M, Panagiotopoulos C, Potts JE, Sandor GG (2010) Primary pulmonary arterial hypertension and autoimmune polyendocrine syndrome in a pediatric patient. <i>Pediatr Cardiol<\/i> 31: 872-874.","DOI":"10.1007\/s00246-010-9704-y"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28.\tNaito A, Terada J, Tanabe N, Sugiura T, Sakao S, <i>et al<\/i>. (2014) Autoimmune hepatitis in a patient with pulmonary arterial hypertension treated with endothelin receptor antagonists. <i>Intern Med<\/i> 53: 771-775.","DOI":"10.2169\/internalmedicine.53.1362"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/12\/64_EJ17-0155\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T02:50:19Z","timestamp":1623207019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/64\/12\/64_EJ17-0155\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej17-0155","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}